On November 12, 2026 Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that it will host a conference call and webcast on Monday, Nov. 16, 2026, at 8:30 a.m. ET to discuss new interim results from REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy), its U.S. multicenter trial exploring the use of Alpha DaRT in patients with recurrent glioblastoma. The call will take place on the back of the presentation of the results at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), to be held Nov. 12-15, 2026, in Philadelphia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The call will feature REGAIN principal investigator Dr. Joshua Palmer of The Ohio State University; Uzi Sofer, CEO of Alpha Tau; Robert Den, MD, Chief Medical Officer of Alpha Tau; and Raphi Levy, CFO of Alpha Tau.
Conference Call and Webcast Details
● Date: Monday, Nov. 16, 2026
● Time: 8:30 a.m. ET
● Web Access: View Source
An archived webcast will be available on the Company’s website following the event.
About the REGAIN Study
The clinical trial is expected to enroll up to 20 U.S. patients with recurrent glioblastoma not amenable to surgical resection who have undergone a prior course of central nervous system radiation. The primary objective of the study is to evaluate the feasibility and safety of the treatment, following the Company’s promising results from pre-clinical studies. Additional information about the trial can be found at View Source
(Press release, Alpha Tau Medical, NOV 12, 2026, View Source [SID1234674664])